Financial Astrology Terminal

Pfizer (PFE) Stock Analysis 2027

An informational overview of Pfizer's business, operating measures and risks.

PFE stockPharmaceuticalsCompany analysis
Pfizer (PFE) analysis illustration
PFE snapshot · as of November 3, 2026 (close) · Price history pages
$30.00about -2.2% on the day
52-week low
$23.62
52-week high
$30.44
Quarterly dividend
$0.43
Exchange
NYSE

Company Overview

Pfizer is a global pharmaceutical company that develops and sells medicines and vaccines in areas including oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases. It trades under the ticker PFE.

Pfizer was founded in New York and grew into one of the world's largest pharmaceutical companies. Through acquisitions such as Warner-Lambert, Pharmacia, Wyeth and Seagen, it expanded its portfolio.

Pfizer partnered with BioNTech to develop a COVID-19 vaccine, which became one of its best-selling products.

Latest Quarterly Results: Q3 2026

Pfizer reported third-quarter 2026 results on November 3, 2026.

Q3 2026 revenue
$16.58B
vs $16.65B a year earlier
Q3 2026 net income
$3.24B
vs $3.54B
Reported diluted EPS
$0.56
adjusted $0.87
Launched and acquired products revenue
$3.8B
+32% operationally
Company outlook, 2026 revenue
$62.0B – $64.0B
management guidance, raised
Quarterly Revenue
USD billions, Q3 2025 vs Q3 2026
Quarterly Net Income
USD billions, Q3 2025 vs Q3 2026

Excluding Comirnaty and Paxlovid, third-quarter revenue grew 7% operationally. GAAP results included a $650 million acquired in-process R&D charge.

The 52-week range shown is as of late October 2026.

Business Model and Revenue Drivers

Revenue rose sharply during the pandemic from COVID-19 vaccine and antiviral sales, then declined as demand fell. Separating COVID products from the rest of the portfolio shows underlying trends.

Several major drugs face patent expirations, after which generic or biosimilar competition usually lowers sales.

Acquisitions, including Seagen in oncology, add products and pipeline candidates intended to offset revenue lost to patent expirations.

Competitive Landscape

Pfizer competes with Merck, Johnson & Johnson, AbbVie, Bristol-Myers Squibb and others across therapeutic areas.

Its research, global distribution and broad portfolio are key strengths.

Revenue Growth and Financial Performance

When reviewing Pfizer's reported results, these measures give the clearest view of growth, profitability and cash generation:

  • Revenue excluding COVID-related products
  • Sales of key drugs and vaccines
  • Pipeline milestones and trial results
  • Cost-reduction program progress
  • Debt levels and dividend coverage

Profitability and Earnings Quality

Revenue growth is only part of the picture. For Pfizer, it helps to check whether growth comes from higher volumes, higher prices or acquisitions, and whether margins are widening or narrowing as the business scales.

Reported earnings can include one-time items such as restructuring charges, asset sales, tax effects or legal settlements. Separating these from recurring operating results, and comparing like-for-like periods, gives a more reliable view of underlying profitability.

Balance Sheet, Debt and Financial Stability

A review of Pfizer's financial position starts with cash, total debt, lease obligations and how operating cash flow compares with capital spending. A business that funds its investment from its own cash flow is in a different position from one that relies on borrowing or issuing new shares.

Changes in inventory, receivables and working capital are also worth monitoring, because they can absorb cash and signal shifts in demand before they appear in revenue.

PFE Stock Valuation Analysis

Measures such as the price-to-earnings ratio, price-to-sales ratio and enterprise value to EBITDA describe how the market is currently pricing Pfizer relative to its results.

However, a single valuation ratio cannot establish whether a stock is undervalued or overvalued. Earnings quality, free cash flow, margins, competitive position and the growth needed to support the current price all need to be considered together, and compared with similar companies.

Business Outlook and Investment Risks

Management guidance and industry conditions shape expectations for Pfizer, but guidance is an estimate rather than an established outcome. Several uncertainties are specific to this business:

  • Patent expirations and generic competition
  • Clinical trial failures
  • Drug pricing regulation
  • Acquisition integration and litigation

From List Price To Net Revenue

A medicine's published list price is only the starting point for understanding what a manufacturer records. In the United States, Pfizer sells through a distribution system that includes wholesalers, pharmacies, hospitals and other providers. Insurers and pharmacy benefit managers influence which medicines are covered and what patients pay. Rebates, discounts and other contractual payments can reduce the amount retained from a sale, so a change in list price alone does not reveal the change in realized revenue.

Financial statements reflect estimates of deductions from gross sales, including rebates and returns. Those estimates depend on contract terms, the mix of purchasers and how products are used. A later adjustment can affect revenue in the period when the estimate changes, even if the underlying product was delivered earlier. Reading the revenue recognition and sales deduction disclosures alongside product sales helps distinguish changes in commercial demand from changes in estimated amounts owed to customers or payers.

Outside the United States, pricing and access arrangements vary by country. Public health systems may negotiate prices, restrict reimbursement to particular uses or require evidence of a treatment's benefit relative to alternatives. Currency translation adds another layer when local sales are reported in dollars. Operational growth measures generally remove the effect of exchange rate movements, but their definitions should be checked in the company's report before comparing them with reported growth.

Research And Development Economics

Drug development moves through laboratory work and successive clinical trial phases before regulators consider an application for marketing approval. Each phase addresses different questions, from initial safety and dosing to evidence of benefit and adverse effects in larger groups. A candidate can fail at any stage, and approval for one condition does not automatically authorize every possible use. Trial design, the patient population and the chosen comparison treatment all matter when interpreting a study result.

Research spending combines work on many candidates, including projects that never produce a marketed medicine. Consequently, a period's research expense cannot be matched neatly with that period's sales. The financial statements generally expense internal research and development as it occurs, while purchased rights and acquired development projects can receive different accounting treatment depending on the transaction. The notes and management discussion help explain why two research investments with similar scientific aims may affect reported earnings differently.

A pipeline table is most informative when read as a collection of distinct projects rather than a simple count. Candidates differ in their stage of development, intended patient group, scientific mechanism and potential competition. Some programs test additional uses for an existing product, while others involve new compounds. Partnerships can also divide development costs and commercial rights, so a successful trial does not necessarily mean Pfizer receives all of the resulting revenue.

Manufacturing And Product Supply

Making a medicine requires more than producing its active ingredient. Manufacturers must maintain controlled processes, test batches, package products correctly and document each step under regulatory quality standards. Vaccines and biologic medicines can be particularly sensitive to production conditions and storage requirements. A plant issue, a shortage of an input or a failed quality test can interrupt supply even when demand is stable, while maintaining backup capacity and quality systems adds cost.

Product mix affects manufacturing economics because medicines differ in production complexity, required facilities and distribution needs. Gross margin therefore reflects more than the selling price of an individual product. It can also change with factory utilization, inventory charges and the mix of products sold. When reviewing cost of sales, the accompanying notes and management explanation can clarify whether a margin movement reflects an ongoing change in the portfolio or a charge associated with a specific event.

Collaboration And Intangible Asset Accounting

Pharmaceutical companies often share rights to a medicine through licensing and collaboration agreements. The party recording a product sale is not always the party retaining all of its economics: another company may receive royalties, a share of profits or milestone payments. Conversely, Pfizer can earn income from rights licensed to a partner without recording the partner's full product sales as its own revenue. Contract disclosures are useful for understanding which activities and payments sit behind each reported line.

Acquisitions can place substantial intangible assets on the balance sheet, including rights to marketed products and development programs. Finite-lived product rights are generally amortized over their estimated useful lives, producing an expense that is separate from current cash spending on research or manufacturing. Goodwill is treated differently and is tested for impairment under applicable accounting rules. An impairment charge signals a reduction in a recorded asset's carrying value, but it is not itself a cash payment in the period recorded.

Conclusion: Is PFE Stock Worth Analyzing in 2027?

Pfizer has a business model with clear drivers that can be tracked through its reported results, and a set of risks that are specific to its industry and financial position.

A balanced assessment considers growth, profitability, balance-sheet strength, valuation and risk together. PFE is a company worth monitoring for what its results reveal about its business.

Frequently asked questions

What is a patent cliff?

A patent cliff occurs when patents on major drugs expire and generic competitors enter, reducing sales.

Why did Pfizer acquire Seagen?

Seagen added cancer treatments and pipeline candidates to Pfizer's oncology portfolio.

What areas does Pfizer focus on?

Pfizer focuses on oncology, vaccines, internal medicine, inflammation and immunology, and rare diseases.